ICOS and non-small cell lung carcinoma: Although one clinical trial reported that treatment of NSCLC patients with anti-PD-1 antibodies nivolumab expanded the levels of effector T cells expressing the costimulatory molecules CD28, CD27, and ICOS (40), we did not observe the similar immuno-logical events (Figure 2B).